ESTRO 2025 - Abstract Book

S2059

Clinical - Urology

ESTRO 2025

Conclusion: Global health and most QoL subdomains remained stable in both arms over the 24-week period. We did observe more fatigue and hormonal treatment-related symptoms in the SBRT+DARO arm. A linear mixed model comparing the arms and the physician reported toxicity will be additionally reported at ESTRO25.

Keywords: prostate cancer, SBRT, oligometastases

References: https://www.clinicaltrials.gov/study/NCT04641078